Labcorp Forecasts Steeper Fall In COVID-19 Testing Sales

• Laboratory Corp of America Holdings (NYSE: LH) posted Q3 revenues of $3.61 billion, a decrease of 11.2% Y/Y, missing the consensus of $3.79 billion.

• The 10.7% decrease in organic revenue was driven by an 11.8% decrease in COVID-19 Testing, partially offset by a 1.1% increase in the company's organic Base Business.

• "We continue to manage inflationary headwinds and labor constraints through our LaunchPad initiatives. And, we are accelerating the planned spin-off of our Clinical Development business to mid-2023 pending customary approvals," said Adam Schechter, chairman & CEO.

• Adjusted operating margin compressed from 22.3% to 16.3%.

• Diagnostic sales decreased 15.7% to $2.21 billion. Total volume (measured by requisitions) decreased by 10.3%.

• The company posted an adjusted EPS of $4.68 versus $6.82 a year ago and a consensus of $4.67.

• Guidance: Labcorp revised FY22 adjusted EPS guidance to $19.25-$20.25 compared to the prior range of $19.00-$21.25.

• The company expects COVID-19 testing sales to decline (59.0%)-(57.0%) versus (60.0%)-(50.0%) expected earlier.

• Price Action: LH shares are down 6.28% at $215.50 on the last check Thursday.

See more from Benzinga

• Baxter Q3 Performance underwhelms Investors, FY22 Guidance Lags Consensus

• Community Health Systems Shares Are Trading Higher After Q3 Earnings

• Garry Kasparov Says Rishi Sunak's First Phone Call As UK PM Was To 'The Leader Of The Free World' — It Wa

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.